伊朗治疗性抗体市场展望：趋势及2025年预测
The Perspective of Therapeutic Antibody Marketing in Iran: Trend and Estimation by 2025.
作者信息
Golpour Monireh, Vatanpour Pouya, Amini Mina, Saeedi Majid, Hafezi Nasim, Rafiei Alireza
机构信息
Molecular and Cell Biology Research Center, Student Research Committee, Faculty of Medicine, Mazandaran University of Medical Science, Sari, Iran.
Oneocean Company, Oslo, Norway.
出版信息
Adv Pharmacol Pharm Sci. 2021 Mar 30;2021:5569590. doi: 10.1155/2021/5569590. eCollection 2021.
BACKGROUND
Monoclonal antibodies with high efficiency and specificity are one of the best strategies to diagnose and treat a variety of diseases such as cancer, autoimmunity, and inflammatory diseases. The market for monoclonal therapeutic antibodies (MTAs) has grown dramatically in the past decade.
OBJECTIVE
Given the importance of these issues, developing countries spend a high cost on importing or producing MTAs annually. This study intends to examine the market of monoclonal therapeutic antibodies in Iran and predict the future growth rate of this market using the obtained data.
METHODS
Data on the status of MTAs in the country (from 2008 to 2018) were obtained from the Food and Drug Deputy of Mazandaran University of Medical Sciences. The market status of MTAs was studied based on the dosage forms, application, and price. Then, the market outlook was predicted up to year 2025.
RESULTS
The results showed that 58.8% of all MTAs were humanized, and 86% of all antibody-based drugs were used to treat cancer. Sales of MTA-based medications will reach $454 million by 2025 and are projected to grow significantly in the future.
CONCLUSION
Given the increasing technology of the production of MTAs and their use in targeted therapies worldwide, their consumption market in Iran is expected to grow significantly.
背景
具有高效性和特异性的单克隆抗体是诊断和治疗多种疾病（如癌症、自身免疫性疾病和炎症性疾病）的最佳策略之一。在过去十年中，单克隆治疗性抗体（MTA）市场急剧增长。
目的
鉴于这些问题的重要性，发展中国家每年在进口或生产MTA方面花费高昂成本。本研究旨在考察伊朗单克隆治疗性抗体市场，并利用所获数据预测该市场未来的增长率。
方法
从马赞德兰医科大学食品药品部门获取该国单克隆治疗性抗体的相关数据（2008年至2018年）。基于剂型、应用和价格对单克隆治疗性抗体的市场状况进行研究。然后，预测了截至2025年的市场前景。
结果
结果显示，所有单克隆治疗性抗体中有58.8%是人源化的，所有基于抗体的药物中有86%用于治疗癌症。到2025年，基于单克隆治疗性抗体的药物销售额将达到4.54亿美元，预计未来还将大幅增长。
结论
鉴于全球单克隆治疗性抗体生产技术的不断提高及其在靶向治疗中的应用，预计其在伊朗的消费市场将大幅增长。
Zotero 插件